CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 80 enrolled
Drug / intervention
Ethanol +1 moredrug
Likely dose
Ethanol 0.8 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03930446
NCT03930446Early Ph 1Completed

Alcohol, Behavior, and Brain Imaging

University of Chicago·interventional·Posted Apr 29, 2019·Updated Apr 25, 2022

In Brief

A Early Phase 1 clinical trial evaluating Ethanol and Placebo for Alcohol Drinking and 6 related conditions. Completed, enrolled 80 participants.

Detailed Summary

To evaluate the relationship of extraversion to both the acute subjective and behavioral effects of alcohol, and the neural reactivity to the anticipation of reward.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Early Ph 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 29, 2019
Enrollment StartJan 1, 2016
Primary CompletionMay 30, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.2 years ago

Interventions

Ethanoldrug

The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water

Placeboother

The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.